Book contents
- Frontmatter
- Contents
- Contributors
- Overview: Biology Is the Foundation of Therapy
- PART I BASIC RESEARCH
- PART II CLINICAL RESEARCH
- 23 Introduction to Clinical Research
- 24 Sarcoma
- 25 Neuroblastoma
- 26 Retinoblastoma
- 27 Primary Brain Tumors and Cerebral Metastases
- 28 Head and Neck Cancer Metastasis
- 29 Cutaneous Melanoma: Therapeutic Approaches for Metastatic Disease
- 30 Gastric Cancer Metastasis
- 31 Metastatic Pancreatic Cancer
- 32 Metastasis of Primary Liver Cancer
- 33 Advances in Management of Metastatic Colorectal Cancer
- 34 Lung Cancer Metastasis
- 35 Metastatic Thyroid Cancer: Evaluation and Treatment
- 36 Metastatic Renal Cell Carcinoma
- 37 Bladder Cancer
- 38 Bone Complications of Myeloma and Lymphoma
- 39 Breast Metastasis
- 40 Gynecologic Malignancies
- 41 Prostate Cancer Metastasis: Thoughts on Biology and Therapeutics
- 42 The Biology and Treatment of Metastatic Testicular Cancer
- 43 Applications of Proteomics to Metastasis Diagnosis and Individualized Therapy
- 44 Critical Issues of Research on Circulating and Disseminated Tumor Cells in Cancer Patients
- 45 Lymphatic Mapping and Sentinel Lymph Node Biopsy
- 46 Molecular Imaging and Metastasis
- 47 Preserving Bone Health in Malignancy and Complications of Bone Metastases
- 48 Role of Platelets and Thrombin in Metastasis
- THERAPIES
- Index
- References
43 - Applications of Proteomics to Metastasis Diagnosis and Individualized Therapy
from PART II - CLINICAL RESEARCH
Published online by Cambridge University Press: 05 June 2012
- Frontmatter
- Contents
- Contributors
- Overview: Biology Is the Foundation of Therapy
- PART I BASIC RESEARCH
- PART II CLINICAL RESEARCH
- 23 Introduction to Clinical Research
- 24 Sarcoma
- 25 Neuroblastoma
- 26 Retinoblastoma
- 27 Primary Brain Tumors and Cerebral Metastases
- 28 Head and Neck Cancer Metastasis
- 29 Cutaneous Melanoma: Therapeutic Approaches for Metastatic Disease
- 30 Gastric Cancer Metastasis
- 31 Metastatic Pancreatic Cancer
- 32 Metastasis of Primary Liver Cancer
- 33 Advances in Management of Metastatic Colorectal Cancer
- 34 Lung Cancer Metastasis
- 35 Metastatic Thyroid Cancer: Evaluation and Treatment
- 36 Metastatic Renal Cell Carcinoma
- 37 Bladder Cancer
- 38 Bone Complications of Myeloma and Lymphoma
- 39 Breast Metastasis
- 40 Gynecologic Malignancies
- 41 Prostate Cancer Metastasis: Thoughts on Biology and Therapeutics
- 42 The Biology and Treatment of Metastatic Testicular Cancer
- 43 Applications of Proteomics to Metastasis Diagnosis and Individualized Therapy
- 44 Critical Issues of Research on Circulating and Disseminated Tumor Cells in Cancer Patients
- 45 Lymphatic Mapping and Sentinel Lymph Node Biopsy
- 46 Molecular Imaging and Metastasis
- 47 Preserving Bone Health in Malignancy and Complications of Bone Metastases
- 48 Role of Platelets and Thrombin in Metastasis
- THERAPIES
- Index
- References
Summary
APPLICATION OF PROTEOMICS AND NANOTECHNOLOGY TO CANCER BIOMARKER DISCOVERY: CLINICAL NEED VERSUS PHYSIOLOGIC ROADBLOCKS
Proteomics Has Potential to Address Need for Specific Cancer Biomarkers
Cancer is too often diagnosed and treated too late, when the tumor cells have already invaded and metastasized. At this stage, therapeutic modalities are limited in their success. Detecting cancers at their earliest stages, even in the premalignant state, means that current or future treatment modalities might have a higher likelihood of a true cure. For example, ovarian cancer is usually treated at an advanced stage. The resulting five-year survival rate is 35 percent to 40 percent for patients with late-stage disease who receive the best possible surgical and chemotherapeutic intervention. In contrast, if ovarian cancer is detected at an early stage, conventional therapy produces a high rate of five-year survival (95%) [1]. Thus, early detection, by itself, could have a profound effect on the successful treatment of this disease. A clinically useful biomarker for early cancer detection should be measurable in a readily accessible body fluid, such as serum [2], urine [3], or saliva [4]. Clinical proteomic methods are especially well suited to discovering such biomarkers [5]. Serum or plasma has been the preferred medium for discovery, because this fluid is a protein-rich information reservoir that contains the traces of what has been encountered by the blood during its constant perfusion and percolation throughout the tissues [6].
- Type
- Chapter
- Information
- Cancer MetastasisBiologic Basis and Therapeutics, pp. 475 - 485Publisher: Cambridge University PressPrint publication year: 2011